Mantle lymphoma: efficacy of a 2nd generation inhibitor of Bruton tyrosine kinase
Acalabrutinib, a highly selective Bruton tyrosine kinase inhibitor, shows clear benefit in relapsed or refractory mantle cell lymphomas.Mantle cell lymphoma ...
Read more